Tecnimede-Sociedade Tecnico-Medicinal S.A.
7
0
0
0
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 45/100
0.0%
0 terminated/withdrawn out of 7 trials
14%
1 trials in Phase 3/4
0%
1 of 0 completed trials have results
Key Signals
Enrollment reporting
Analytics
Activity Timeline
Global Presence
Clinical Trials (7)
Drug-Drug Interaction between Empagliflozin 25 mg Film-Coated Tablets and Alogliptin 25 mg Film-Coated Tablets in Healthy Participants Under Fasting Conditions
Role: lead
Bioequivalence of Canagliflozin 300 mg Film-Coated Tablets in Healthy Participants Under Fasting Conditions.
Role: lead
Study of a DPP 4 inhibitor and an SGLT2 inhibitor used together compared with each treatment alone in adults with type 2 diabetes treated with metformin.
Role: lead
Drug-Drug Interaction between Alogliptin 25 mg Film-Coated Tablets and Empagliflozin 25 mg Film-Coated Tablets in Healthy Participants Under Fasting
Role: lead
Comparative Bioavailability of Teriflunomide 14 mg Film-Coated Tablets: A Single-Dose, Open-Label, Randomized, Two-Sequence, Two-Treatment, Two-Period Crossover Study in Healthy Subjects Under Fasting Conditions.
Role: lead
Bioequivalence of Linagliptin 5 mg Film-Coated Tablets in Healthy Participants Under Fasting Conditions
Role: lead
Comparative Bioavailability of Empagliflozin 25 mg Film-Coated Tablets: A Single-Dose, Open-Label, Randomized, Two-Sequence, Two-Treatment, Two-Period Crossover Study in Healthy Subjects Under Fasting Conditions.
Role: lead
All 7 trials loaded